NCT04740918: A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

NCT04740918
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: PD-L1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have had prior treatment with trastuzumab (+/- pertuzumab) & a taxane
Exclusions: Patients with more than two prior lines of therapy in the metastatic setting; Patients with prior treatment of trastuzumab emtansine (e.g. T-DM1, Kadcyla) in the metastatic setting; Patients with symptomatic, untreated, or actively progressing CNS metastases – see trial for details; Patients with a history of leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04740918

Comments are closed.

Up ↑